Aztiq Pharma Partners, a private equity fund led by Róbert Wessman, announced in the beginning of July that it has completed a 100 million USD financing to purchase a newly issued share equity in Alvogen US.
Morgan Stanley led the financing, which was subscribed by international institutional investors. The capital was used by Aztiq to buy a 17% stake in Alvogen US, at Fora pre-money valuation of 350 million USD.
“The new equity will allow Alvogen’s generic business and its branded division Almatica Pharma to increase the R&D investment and expand branded sales channels in the US market,” says Lisa Graver, president of Alvogen’s North America business.
Accelerate growth R&D and US sales & marketing platform
Almatica Pharma was established by Alvogen in 2017. Almatica is focused on the development, production, and marketing of novel treatments for serious central nervous system (CNS) diseases. Almatica’s mission is to meaningfully improve the lives of patients around the world, by bringing to market a portfolio of novel CNS therapeutics.
Prior to the share issue, Alvogen US was 100% owned by Alvogen Lux Holdings. Following Aztiq Pharma Partners’ acquisition of these newly issued shares, Aztiq Pharma Partners holds a combined direct and indirect, stake of approximately 40% in Alvogen US.
“Alvogen US is a very exciting investment opportunity. Many pipeline products are coming to the market in the next two years. Aztiq’s vision is to increase patient access to the best medicines and to improve people’s lives. With Aztiq’s new investment in Alvogen US, the company can accelerate the growth of its R&D and sales & marketing platform in the US market,” says Róbert Wessman.
Photo of Robert Wessman: Alvotech